MedTrace Logo

Trial of Mesalamine for the Treatment of Active Microscopic Colitis

NCT00952952 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2011-05-24

No results posted yet for this study

Summary

Subjects must be 18 years old and older, have diarrhea and microscopic colitis. Pregnant or nursing females are excluded. They can't have other untreated diarrheal conditions. Subjects will receive medication for 8 weeks, followed by sigmoidoscopy with biopsies. The subjects will be monitored weekly. A pathologist will review pre and post treatment biopsies. Subjects that show improvement will be followed for 4 weeks post medication.

Conditions

Interventions

DRUG

Mesalamine

Sponsors & Collaborators

  • Paul E. Evans MD

    collaborator UNKNOWN

  • William J. Sandborn MD

    collaborator UNKNOWN

  • Edward V. Loftus MD

    collaborator UNKNOWN

  • Thomas C. Smryk MD

    collaborator UNKNOWN

  • Willaim Tremaine MD

    collaborator UNKNOWN

  • Mayo Clinic

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00952952 on ClinicalTrials.gov